ARJO-B.ST
Strong BuyFull HouseAI neutralArjo AB (publ) · Healthcare · Sweden · $792M
SEK 26.66 -1.1% · close 5 Oct · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Arjo makes patient handling, hospital beds and pressure-care equipment, which demand from ageing populations supports. Main shareholder Carl Bennet has bought shares worth about SEK 125 million and SEK 42 million, a clear sign of owner confidence, and the shares look cheap. However, profitability has repeatedly fallen short of expectations and consensus earnings were cut 3.4% over about a month, so the improvement in margins is not yet proven.
ABOUT ARJO AB (PUBL)
Read
Arjo AB develops, manufactures, and sells medical devices and solutions for patient handling, hygiene, disinfection, medical beds, and venous thromboembolism (VTE) prevention. The company holds a strong market position in acute and long-term care settings, leveraging its extensive product portfolio and global distribution network to improve patient mobility and safety. Arjo is a specialized healthcare provider committed to enhancing clinical outcomes and caregiver efficiency.
FINANCIAL SUMMARY (SEK)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 10.0B | 11.0B | 11.3B | 11.0B | 3.3% | 10.9B | 11.2B | 11.6B | 2.8% |
| EPS (SEK) | — | 1.65 | 1.76 | 1.83 | 1.23 | -9.3% | 1.41 | 1.51 | 1.78 | 20.2% |
| Shares | — | 272.4M | 272.4M | 272.4M | 272.4M | 0.0% | 254.2M | — | — | — |
| Debt | 118.0M | 6.3B | 5.5B | 5.4B | 5.4B | 159.5% | 5.6B | — | — | — |
| Equity | — | 7.4B | 7.6B | 8.3B | 7.5B | 0.1% | — | — | — | — |
| Op CF | — | 827.0M | 2.1B | 1.5B | 1.4B | 20.2% | 1.5B | — | — | — |
| Inv CF | — | -813.0M | -637.0M | -635.0M | -705.0M | — | — | — | — | — |
| Fin CF | — | 136.0M | -1.4B | -907.0M | -730.0M | — | — | — | — | — |
Calmer than 84% of stocks we rank over the past year (24% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARJO-B.ST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARJO-B.ST | Arjo AB (publ)(you) | $792M | 92 | Strong Buy |
| ASKER.ST | Asker Healthcare Group AB (publ) | $2.4B | 67 | Buy |
| SYNSAM.ST | Synsam AB (publ) | $762M | 91 | Strong Buy |
| APOTEA.ST | Apotea AB (publ) | $860M | 81 | Strong Buy |
| AMBEA.ST | Ambea AB (publ) | $1.3B | 86 | Strong Buy |
| HUM.ST | Humana AB (publ) | $327M | 88 | Strong Buy |
| BIOG-B.ST | BioGaia AB (publ) | $1.1B | 77 | Buy |
| ATT.ST | Attendo AB (publ) | $1.8B | 86 | Strong Buy |
| CEVI.ST | CellaVision AB (publ) | $404M | 81 | Strong Buy |
| VIMIAN.ST | Vimian Group AB (publ) | $1.9B | 84 | Strong Buy |
Peer medians: ROE 4.1% · P/E 33.9x · Gross margin 66.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.